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Purpose:Allergicrhinitis(AR)isregardedasariskfactorforasthmaandbronchialhyperresponsiveness(BHR)isfrequentlyobserved
inpatientswithAR.ThepurposeofthisstudyistoanalyzethecharacteristicsofARpatientswithBHRandidentifyfactorsthatcon-
tributetotheincidenceofBHR.
Methods:Themedicalrecordsofatotalof176childrenwithARwereanalyzedretrospectively.Allpatientswereevaluatedbyper-
formingspirometryandamethacholinechallengetest.
Results:Onehundredandfifty-fivepatients(88%)wereclassifiedastheBHR-negativegroupand21patients(12%)wereclassified
astheBHR-positivegroup.Forcedexpiratoryflowbetween25%and75%ofvitalcapacity(FEF25-75%predicted)wasreduced,andto-
taleosinphilcounts,totalimmunoglobulinE(IgE)level,andserumspecificIgElevelsofDermatophagoides pteronyssinusandDer-
matophagoides farinaewerehigherintheBHR-positivegroupcomparedtotheBHR-negativegroup.However,FEF25-75wastheonly
statisticallysignificantpredictorforthepresenceofBHRonmultivariatelogisticregressionanalysis.Thecutoffvaluetodistinguish
BHR-positivesubjectsobtainedfromareceiveroperatingcharacteristicscurveofFEF25-75was88.4%.AhigherfrequencyofBHRwas
foundinthegroupwithaFEF25-75lessthan88.4%,andthesensitivity,specificity,positivepredictivevalueandnegativepredictive
valuewere57.1%,80.6%,28.6%,and93.3%,respectively.
Conclusion:ReducedFEF25-75valuesinchildrenwithARcanbehelpfulinpredictingBHR.ChildrenwithlowFEF25-75inspirometric
testsshouldbefollowedcloselyforapparentonsetofclinicalsymptomsofasthma.(�������� ������ ������ ����(���������������
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INTRODUCTION
Allergic	rhinitis	(AR)	is	characterized	by	typical	symptoms	in-
duced	by	nasal	immunoglobulin	E	(IgE)-mediated	inflammatory	
response	after	allergen	exposure.1)	Symptoms	of	AR	can	affect	
quality	of	life	more	than	symptoms	of	asthma	do,2)	and	the	preva-
lence	in	children	reaches	23.4%	to	31.2%.3,4)	Asthma	and	AR	are	
known	to	be	closely	related,5)	and	AR	is	regarded	as	a	risk	factor	
for	the	incidence	of	asthma.6)	Since	AR	often	precedes	or	is	associ-
ated	with	asthma,	the	World	Health	Organization	document,	“Al-
lergic	Rhinitis	and	its	Impact	on	Asthma	(ARIA),”7)	emphasized	
the	role	of	AR	as	a	risk	factor	in	the	development	of	asthma	and	
recommended	exploration	of	bronchial	involvement	in	patients	
with	AR.	
As	abnormalities	of	spirometric	parameters	are	exhibited	by	AR	
patients	without	asthma,	impaired	values	of	forced	expiratory	vol-
ume	in	1	second	(FEV1)	can	be	detected,3)	and	airway	reversibility	
evidenced	by	increased	FEV1	after	a	bronchodilator	test	has	been	
reported.8)	AR	patients	are	also	reported	to	have	reduced	forced	
expiratory	flow	between	25%	and	75%	of	vital	capacity	(FEF25-75)	as	
an	early	marker	of	bronchial	damage.9)	These	findings	are	sugges-
tive	of	bronchial	involvement	and	damage	in	patients	with	AR	
without	obvious	symptoms	of	asthma.	In	addition,	nasal	lavage	of	
asthmatic	children	showed	Th2	polarization,	which	confirmed	
there	is	a	pathophysiologic	link	between	the	upper	and	lower	air-
way.10)	It	also	has	been	reported	that	there	is	an	association	be-
tween	nasal	allergic	inflammation	maintained	by	eosinophil	infil-
tration	and	bronchial	obstruction	indicated	by	an	reduced	FEV1.11)
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Bronchial	hyperresponsiveness	(BHR)	to	natural	stimuli	such	
as	exercise	or	chemical	stimuli	such	as	histamine	or	methacholine	
is	a	characteristic	feature	of	asthma,12)	and	it	is	associated	with	an	
inflammatory	response	in	the	lower	respiratory	tract	in	patients	
with	asthma.13)	BHR	is	observed	in	more	than	one	third	of	AR	pa-
tients,14-16)	and	children	with	AR	are	more	likely	to	have	BHR	com-
pared	to	children	without	AR.4)	BHR	to	methacholine	among	rhi-
nitics	is	associated	with	subclinical	asthma,17)	and	AR	patients	with	
BHR	are	at	significantly	higher	risk	of	developing	asthma	com-
pared	to	patients	with	normal	bronchial	provocation	test	results.18)	
Factors	that	can	affect	the	development	of	BHR	in	patients	with	
AR	include	nasal	inflammation,19)	the	duration	of	AR,20)	positive	
skin	prick	test	(SPT)	reactions	to	a	larger	number	of	allergens,14)	
total	IgE	levels,21)	sputum	eosinophil	counts,22)	perennial	type	of	
rhinitis,15)	low	FEF25-75,23)	low	FEF25-75/forced	vital	capacity	(FVC)	
ratio,24)	positive	bronchodilation	test	results,25)	a	family	history	of	
asthma15)	and	a	family	history	of	BHR.26)
There	has	been	a	lot	of	researches	on	the	predictors	of	BHR	in	
patients	with	AR	but	this	is	the	first	time	in	Korean	pediatric	pa-
tients	with	short	duration	of	AR	and	relatively	good	lung	function	
compared	to	patients	with	asthma.	The	purpose	of	this	study	is	to	
analyze	the	characteristics	of	AR	patients	with	BHR	who	are	
thought	to	be	at	a	higher	risk	of	developing	asthma	compared	with	
those	without	BHR	and	to	identify	factors	that	contribute	to	the	
incidence	of	BHR.	
MATERIALS AND METHODS
1. Subjects
The	Severance	Hospital	Institutional	Review	Board	approved	
this	study,	and	informed	consent	was	obtained	from	the	parents	of	
the	children.	The	medical	records	of	176	children	between	the	ages	
of	5	and	16	years	who	visited	Severance	Children’s	Hospital	Pedi-
atric	Allergy	Clinic	and	diagnosed	with	AR	were	analyzed	retro-
spectively.	The	diagnosis	of	AR	was	made	based	on	a	history	of	
symptoms	including	rhinorrhea,	sneezing,	nasal	congestion	and	
itching	apart	from	colds	and	positive	SPT	response	results	or	the	
presence	of	allergen	specific	serum	IgE	(sIgE)	to	one	or	more	aero-
allergens.9)	Exclusion	criteria	included	asthma	symptoms	such	as	
cough,	wheezing,	dyspnea	and	shortness	of	breath,	asthma	previ-
ously	diagnosed	by	a	physician,	acute	or	chronic	respiratory	infec-
tions,	and	the	use	of	nasal	or	inhaled	corticosteroids	during	the	
previous	four	weeks.	
We	divided	them	into	patients	with	BHR	and	those	without	
BHR	and	compared	the	two	groups.	In	addition,	peripheral	blood	
total	eosinophil	counts	(TEC),	total	serum	IgE	levels	and	sIgE	tests	
were	measured.	TEC	were	measured	with	a	Sysmex	XE-2100	auto-
mated	blood	cell	analyzer	(Sysmex,	Kobe,	Japan)	and	total	serum	
IgE	and	sIgE	levels	were	determined	by	the	CAP	radioallergosor-
bent	technique	(UniCAP,	Pharmacia,	Uppsala,	Sweden).	
sIgE	tests	for	the	six	most	common	allergens	in	Korea	(Derma-
tophagoides pteronyssinus,	Dermatophagoides farinae,	egg	whites,	
cow’s	milk,	German	cockroach	and	Alternaria)	were	performed	
in	168	children.	Atopy	was	defined	as	total	IgE	levels	greater	than	
150	IU/mL	or	sIgE	levels	for	one	or	more	allergens	greater	than	
0.35	KU/L.	In	108	children	seven	years	of	age	or	older,	SPT	were	
performed	using	12	common	aeroallergens:	house	dust	mites	(D. 
pteronyssinus,	D. farinae),	animal	dander	(cat	epithelia,	dog	epi-
thelia),	pollen	(mugwort,	rye	grass,	ragweed,	alder,	oak),	mold	
(Aspergillus fumigatus,	Alternaria alternata),	and	cockroach	
(Blatella germanica).	After	dropping	the	allergen	solutions	on	the	
children’s	backs,	a	skin	prick	was	performed	using	26	G	needles.	
Histamine	and	isotonic	solution	were	used	as	positive	and	nega-
tive	controls,	respectively,	and	an	average	wheel	diameter	greater	
than	3	mm	measured	15	minutes	after	performing	the	test	was	de-
fined	as	positive.	A	positive	SPT	response	for	one	or	more	allergens	
was	also	defined	as	atopy.	
2. Spirometry and methacholine challenge test (MCT)
Spirometry	was	performed,	short-acting	bronchodilator	re-
sponses	were	measured	to	evaluate	bronchial	reversibility,	and	
MCTs	were	performed	to	evaluate	BHR	in	all	patients.
Spirometry	was	performed	using	a	Jaeger	MasterScreen	IOS	
(Jaeger,	Wurzburg,	Germany).	FEV1,	FVC,	FEV1/FVC,	and	FEF25-75	
were	measured	before	and	after	bronchodilator	inhalation	accord-
ing	to	the	American	Thoracic	Society	guidelines.27)	Maximum	val-
ues	among	the	three	FVC	maneuvers	were	recorded.	A	broncho-
dilation	test	was	performed	using	400	μg	of	salbutamol.	ΔFEV1	
was	defined	as	the	value	of	change	in	percent	predicted	FEV1	after	
salbutamol	inhalation	multiplied	by	100	divided	by	the	value	of	
baseline	percent	predicted	FEV1.	Likewise,	Δ	FEF25-75	was	defined	
as	the	value	of	change	in	percent	predicted	FEF25-75	after	salbutamol	
inhalation	multiplied	by	100	divided	by	the	value	of	baseline	per-
cent	predicted	FEV1.	The	reference	values	of	spirometric	parame-
ters	were	based	on	the	previous	paper.28)
MCT	was	performed	according	to	standardized	procedures.	
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Methacholine	(Sigma	Chemical,	St	Louis,	MO,	USA)	was	dissolved	
in	a	buffered	saline	solution	at	several	concentrations	(0.075,	0.15,	
0.31,	0.62,	1.25,	2.5,	5,	10,	25,	50	mg/mL)	and	inhaled	five	times	us-
ing	a	dosimeter	with	an	increase	in	concentration	at	five-minute	
intervals.	The	concentration	was	increased	until	the	FEV1	de-
creased	more	than	20%	compared	to	that	after	buffered	saline	in-
halation	or	the	maximum	cumulative	dose	had	been	administered.	
The	provocative	concentration	causing	a	20%	decrease	in	FEV1	
(PC20)	was	calculated	using	a	dose-response	curve.	Subjects	were	
considered	to	have	BHR	to	methacholine	if	their	PC20	was	less	
than	16	mg/mL.	The	PC20	was	recorded	as	100	mg/mL	unless	the	
FEV1	decreased	by	more	than	20%	after	inhalation	of	the	maxi-
mum	methacholine	concentration	of	50	mg/mL.
3. Statistical analysis
Data	are	expressed	as	the	mean±standard	deviation	if	they	fol-
lowed	a	normal	distribution	and	as	the	median	(interquartile	
range	[IQR])	if	they	showed	a	skewed	distribution.	Categorical	
variables	were	expressed	as	counts	(percentages).	Distributions	
were	examined	for	normality	using	the	Shapiro-Wilk	test.	Contin-
uous	variables	were	compared	between	the	BHR-positive	and	
BHR-negative	groups	using	Student’s	t-test	if	they	were	normally	
distributed	and	the	Mann-Whitney	U	test	otherwise.	Categorical	
variables	were	compared	between	the	two	groups	using	the	chi-
square	test	or	Fisher’s	exact	test.
Logistic	regression	analysis	was	used	to	identify	predictive	fac-
tors	for	positive	BHR.	Each	variable	was	first	analyzed	using	uni-
variate	regression	analysis,	and	variables	with	a	P-value	<0.1	were	
included	in	the	multivariate	logistic	regression	model	after	exclud-
ing	multicollinearity.	Odds	ratio	(OR)	and	95%	confidence	inter-
val	(CI)	were	obtained	for	the	selected	variables,	and	the	results	
were	adjusted	for	age	and	gender.	
A	receiver	operating	characteristics	(ROC)	curve	was	generated	
to	test	the	validity	of	FEF25-75	as	a	means	to	distinguish	between	
positive	and	negative	BHR	subjects,	and	the	area	under	the	curve	
(AUC)	and	its	95%	CI	were	calculated.	The	cutoff	value	was	ob-
tained	from	the	curve	using	the	Youden	method.	Patients	were	
subsequently	divided	into	two	groups	according	to	the	cutoff	value	
and	the	frequency	of	BHR	was	compared	between	groups	with	the	
chi-square	test.	P-values	<0.05	were	considered	statistically	sig-
nificant,	and	statistical	analyses	were	done	using	PASW	ver.	18.0	
(IBM	Co.,	Armonk,	NY,	USA).
RESULTS
Among	a	total	of	176	patients,	155	patients	(88%)	were	classified	
as	the	BHR-negative	group	and	21	patients	(12%)	were	classified	as	
the	BHR-positive	group.	Table	1	shows	a	comparison	of	demo-
graphic	characteristics,	spirometric	parameters,	laboratory	results	
and	frequency	of	the	number	of	positive	SPT	reactions	between	the	
two	groups.	Age,	gender,	height,	and	weight	did	not	differ	between	
the	two	groups.	The	median	PC20	value	in	the	BHR-positive	group	
was	5.74	(IQR,	3.96	to	10.0).	FEV1	%predicted,	ΔFEV1,	FEV1/FVC,	
Δ	FEF25-75	and	the	other	spirometric	parameters	did	not	differ	be-
tween	the	two	groups,	whereas	FEF25-75	%predicted	in	the	BHR-
positive	group	was	significantly	lower	(P= 0.012)	compared	to	the	
BHR-negative	group.	Of	the	laboratory	results,	both	total	IgE	lev-
Table 1. Patient demographic and clinical characteristics
Characteristic BHR-negative (n=155)
BHR-positive 
(n=21) P-value
Male sex 99 (63.9) 16 (76.2) 0.266
Age (yr) 9 (7–10.8) 7.6 (6.4–9.8) 0.174
Height (cm) 134 (124–146) 130 (122–139) 0.223
Weight (kg) 32 (25.5–43) 29 (23–36) 0.181
PC20 (mg/mL) 5.74 (3.96–10.0)
Spirometric parameters
FEV1 %predicted 105.3 (95.3–114.2) 100 (92.5–106.6) 0.093
ΔFEV1 % 2.5 (0–5.6) 4 (1.1–6.7) 0.177
FEV1/FVC % 91.2 (87.0–96.2) 88.2 (84.5–96.8) 0.390
FEF25-75 %predicted 105.1 (91.9–120.0) 87.9 (81.3–107.6) 0.012
ΔFEF25-75 % 12.6 (5.7–22.1) 20.4 (2.2–29.2) 0.127
Laboratory results
Total IgE (kU/L) 256 (147–493.5) 416 (377–1205) < 0.0001
TEC (μL-1) 360 (190–560) 530 (400–825) 0.002
Dermatophagoides pteronys-
sinus (kU/L)
12.3 (1.0–35.1) 28.7 (10.0–72.6) 0.032
Dermatophagoides farinae 
(kU/L)
33.6 (2.7–73.8) 82.7 (26.3–150) 0.011
No. of positive SPT reactions (total 108 subjects)
0 10 (10.4) 0 (0)
1 6 (6.2) 0 (0)
2 33 (34.4) 6 (50)
3 21 (21.9) 2 (16.7)
4 12 (12.5) 3 (25)
≥ 5 14 (14.6) 1 (8.3) 0.499
Values are presented as number (%) or median (interquartile range). Continuous 
variables were compared using the Mann-Whitney U test and categorical variables 
were compared using the chi-square test or Fisher’s exact test.
PC20, provocative concentration causing a 20% decrease in FEV1; FEV1, forced expira-
tory volume in one second; FVC, forced vital capacity; FEF25-75, forced expiratory flow 
between 25% and 75% of vital capacity; IgE, immunoglobulin E; TEC, total eosino-
phil count; SPT, skin prick test.
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els	(P<0.0001)	and	TEC	(P= 0.002)	were	significantly	higher	in	
the	BHR-positive	group,	as	were	sIgE	levels	for	D. pteronyssinus	
(P= 0.032)	and	D. farinae	(P= 0.011).	When	the	SPT	results	ac-
cording	to	the	number	of	positive	reactions	(1,	2,	3,	4,	and	≥5)	
were	compared,	the	frequency	distribution	was	not	significantly	
different	between	the	two	groups.	SPT	was	performed	in	108	pa-
tients,	all	patients	with	negative	SPT	results	showed	a	positive	re-
action	in	the	serological	tests.
When	analyzed	by	univariate	regression,	the	variables	with	a	P-
value	<0.1	were	FEF25-75	%predicted	(OR,	0.972;	95%	CI,	0.949	to	
0.996;	P= 0.023),	total	IgE	(OR,	1.001;	95%	CI,	1.000	to	1.001;	
P= 0.044),	TEC	(OR,	1.001;	95%	CI,	1.000	to	1.003;	P= 0.023),	and	
sIgE	levels	for	D. pteronyssinus	(OR,	1.010;	95%	CI,	1.000	to	1.019;	
P= 0.049)	and	D. farinae	(OR,	1.011;	95%	CI,	1.003	to	1.019;	P=
0.009).	The	results	of	multivariate	logistic	regression	analysis	of	the	
variables	that	were	significant	on	univariate	analysis	(FEF25-75,	to-
tal	IgE,	TEC,	and	sIgE	for	D. farinae),	adjusting	for	age	and	gen-
der,	are	shown	in	Table	2.	FEF25-75	%predicted	(OR,	0.973;	95%	CI,	
0.948	to	1.000;	P= 0.046)	was	the	only	variable	found	to	be	statisti-
cally	significant.	
Fig.	1	shows	the	ROC	curve	of	FEF25-75	for	predicting	the	pres-
ence	of	BHR.	The	AUC	was	0.669	(95%	CI,	0.543	to	0.794;	P=
0.012)	and	the	optimal	cutoff	value	for	distinguishing	patients	
with	BHR	was	88.4%.	Table	3	shows	a	comparison	of	the	frequen-
cy	of	BHR	between	the	two	groups	divided	based	on	this	cutoff	
value.	A	higher	frequency	of	BHR	was	found	in	the	group	with	an	
FEF25-75	less	than	88.4%	(P<0.0001),	and	the	sensitivity,	specificity,	
positive	predictive	value	(PPV)	and	negative	predictive	value	(NPV)	
were	57.1%,	80.6%,	28.6%,	and	93.3%,	respectively.	
DISCUSSION
AR	and	asthma	can	be	considered	one	disease	taking	place	in	
two	parts	of	the	respiratory	system.29)	Airway	reversibility	to	a	
bronchodilator16)	and	BHR,14,23)	which	are	paramount	features	of	
asthma,	are	often	observed	in	patients	with	AR,	suggesting	a	link	
between	AR	and	asthma.	Therefore,	this	study	was	performed	to	
obtain	data	to	inform	the	treatment	and	monitoring	of	patients	
with	AR	at	a	higher	risk	of	developing	asthma	by	analyzing	the	
characteristics	of	children	who	visited	the	Pediatric	Allergy	Clinic	
and	were	diagnosed	with	AR	and	identifying	predictors	for	the	
presence	of	BHR.	As	a	result,	21	of	176	pediatric	patients	(12%)	
who	were	diagnosed	as	having	only	AR	had	BHR.	FEF25-75	%pre-
dicted,	total	IgE,	TEC,	and	serum	sIgE	levels	of	D. pteronyssinus	
and	D. farinae	differed	between	the	BHR-positive	and	BHR-nega-
tive	groups,	but	of	these	variables,	FEF25-75	%predicted	was	the	only	
statistically	significant	predictor	for	the	presence	of	BHR.	Unlike	a	
previous	study,14)	the	distributions	of	the	number	of	SPT-positive	
reactions	did	not	differ	significantly	between	the	two	groups	and	
the	cutoff	value	obtained	from	the	ROC	curve	of	FEF25-75	for	iden-
tifying	BHR-positive	subjects	was	88.4%	with	a	sensitivity	of	
Table 2. Results of multivariate logistic regression analysis
Factor OR (95% CI) P-value
FEF25-75 %predicted 0.973 (0.948–1.000) 0.046
Total immunoglobulin E 1.000 (0.999–1.001) 0.875
Total eosinophil count 1.001 (1.000–1.003) 0.143
Dermatophagoides farinae 1.008 (0.997–1.018) 0.144
OR, odds ratio; CI, confidence interval; FEF25-75, forced expiratory flow between 25% 
and 75% of vital capacity.
Table 3. Frequency of bronchial hyperresponsiveness in patients stratified ac-
cording to their forced expiratory flow between 25% and 75% of vital capacity 
levels
BHR
Total
Positive Negative
FEF25-75
< 88.4 12 30 42
≥88.4 9 125 134
Total 21 155 176
The frequency of BHR in each group was compared with the chi-square test.
BHR, bronchial hyperresponsiveness; FEF25-75, forced expiratory flow between 25% 
and 75% of vital capacity.
Fig. 1. Receiver operating characteristics curve of forced expiratory flow be-
tween 25% and 75% of vital capacity as a diagnostic test for bronchial hyper-
responsiveness. The area under the curve was 0.669 (95% confidence interval, 
0.543 to 0.794; P=0.012) and the optimal cutoff value to distinguish patients 
with bronchial hyperresponsiveness was 88.4%.
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57.1%,	specificity	of	80.6%,	PPV	of	28.6%	and	NPV	of	93.3%.
Even	though	some	studies	showed	that	residual	volume/total	
lung	capacity	ratio	indicating	that	the	degree	of	hyperinflation	re-
flected	the	severity	of	airway	obstruction,30)	FEF25-75	is	thought	to	
correspond	to	the	peripheral	airway	caliber	and	has	been	pro-
posed	as	a	more	sensitive	parameter	than	the	FEV1	for	assessing	
the	presence	of	a	small	airway	obstruction.31)	A	low	FEF25-75	in	the	
setting	of	a	normal	FEV1	is	associated	with	increased	asthma	se-
verity,	systemic	steroid	use,	and	asthma	exacerbations	in	chil-
dren.32)	Impaired	FEF25-75	has	been	reported	as	a	marker	of	early	
bronchial	pathology	in	patients	with	AR,9)	and	studies	on	the	sig-
nificance	of	this	parameter	have	also	been	done	in	rhinitics.	FEF25-
75	has	been	reported	to	decrease	significantly	as	the	duration	of	AR	
increases,33)	and	another	study	proposed	that	a	greater	than	40%	
decrease	in	FEF25-75	may	be	a	more	useful	tool	to	assess	BHR	in	
MCT	rather	than	a	20%	decrease	in	FEV1	in	patients	with	AR.34)
Impaired	FEF25-75	less	than	65%	of	the	predicted	value	was	a	pre-
dictive	of	severe	BHR	(PC20	<1	mg/mL)	in	adolescents	with	AR,35)	
and	the	best	FEF25-75	cutoff	value	to	distinguish	patients	with	both	
airway	reversibility	and	severe	BHR	was	reported	to	be	58.5%	in	a	
study	of	adults	patients	with	AR.25)	The	value	of	FEF25-75	with	the	
greatest	sensitivity	and	specificity	to	detect	a	20%	increase	in	FEV1	
was	68%	in	a	study	conducted	in	asthmatic	children.36)	The	opti-
mal	cutoff	value	of	FEF25-75	to	predict	the	presence	of	BHR	was	
88.4%	in	the	present	study.	This	cutoff	value	is	relatively	high	com-
pared	to	previous	studies	and	this	is	thought	to	be	due	to	the	dif-
ferences	in	study	subjects’	characteristics	and	outcome.	In	this	
study,	the	median	age	of	the	BHR-negative	group	and	BHR-posi-
tive	group	was	less	than	10	and	children	with	short	duration	AR	
compared	with	adults	were	only	included.37)	The	subjects	of	this	
study	had	relatively	good	lung	function	while	previous	studies	ex-
amined	adults	with	longer	duration	AR	or	asthmatic	children.	In	
addition,	outcomes	of	previous	studies	were	severe	BHR	(PC20	<1	
mg/mL)23)	or	both	airway	reversibility	and	severe	BHR25)	whereas	
the	outcome	of	this	study	was	BHR	(PC20	<16	mg/mL).
In	this	study,	12%	of	the	total	subjects	showed	positive	BHR.	
Previous	studies	showed	a	high	frequency	of	BHR	ranging	from	
39%	to	62%,14,19)	and	in	a	study	of	the	general	population	from	8	to	
73	years	old,	BHR-positive	rate	of	26%	was	demonstrated.38)	The	
results	of	the	present	study	is	thought	to	be	due	to	differences	in	
the	subjects’	characteristics.	
One	of	the	limitations	of	this	study	is	that	patients	were	retro-
spectively	reviewed	based	on	medical	records	without	follow-up.	
Longitudinal	studies	are	needed	to	confirm	the	conclusion	that	
patients	with	only	AR	and	low	FEF25-75	have	a	higher	risk	of	BHR	
and	they	actually	are	likely	to	present	with	asthmatic	symptoms	in	
the	future.	In	addition,	it	will	be	shown	whether	the	shifting	from	
BHR-negative	to	BHR-positive	group	in	children	with	AR	can	oc-
cur	through	longitudinal	studies.	Since	AR	and	asthma	frequently	
exist	simultaneously,39)	it	was	important	to	exclude	subjects	with	
undetected	asthma,	which	coexists	with	AR,	by	examining	their	
medical	records	thoroughly	to	screen	for	symptoms	suggestive	of	
asthma.	However,	the	retrospective	review	was	limited.	In	addi-
tion,	according	to	previous	studies,	patients	with	perennial	rhinitis	
had	a	higher	risk	of	BHR	than	patients	with	seasonal	rhinitis15)	and	
BHR	increased	two-fold	during	pollen	season	in	patients	with	sea-
sonal	AR,40)	suggesting	the	type	of	AR	and	seasonality	could	affect	
BHR.	Moreover,	the	duration	of	AR	can	affect	the	degree	of	BHR,	
but	these	factors	were	not	identified	in	the	patients’	medical	re-
cords	and	were	therefore	not	considered	in	the	analysis.	
In	conclusion,	the	lower	airway	in	patients	with	AR	should	be	
carefully	evaluated	because	they	often	present	with	impaired	spi-
rometric	parameters	and	BHR.	This	study	emphasizes	the	role	of	
FEF25-75	in	patients	suffering	from	AR,	and	suggests	that	reduced	
FEF25-75	values	in	children	with	AR	can	be	helpful	in	predicting	
BHR.	It	is	difficult	to	perform	MCT	in	all	children	with	AR	who	
have	only	nasal	symptoms	because	they	do	not	show	BHR	in	most	
cases.	Therefore,	it	seems	most	cost-effective	to	perform	MCT	only	
in	AR	patients	whose	FEF25-75	values	are	low.	Children	with	low	
FEF25-75	values	on	spirometric	tests	should	be	followed	closely	for	
apparent	onset	of	clinical	symptoms	of	asthma.	The	results	of	this	
study	will	be	helpful	in	identifying	high	risk	patients	with	AR	who	
show	BHR	and	treating	and	monitoring	them	appropriately.	Ad-
ditional	longitudinal	studies	and	intervention	studies	to	assess	the	
incidence	of	asthma	as	an	outcome	will	facilitate	the	understand-
ing	of	the	mechanism	underlying	these	diseases	and	enable	appro-
priate	evaluation	and	accurate	treatment	in	each	patient.
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